Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …

The morning blood pressure surge (MBPS) has been shown to be an independent predictor
of cardiovascular events. There is insufficient evidence on the effect of nebivolol, a …

Carvedilol is a new cardiovascular compound with the combined pharmacologic properties
of nonselective β-blockade and vasodilation. The aim of this study was to compare the safety …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

To treat hypertension, combining two or more antihypertensive drugs from different classes
is often necessary. β-Blockers and renin–angiotensin–aldosterone system inhibitors, when …

Objective: To estimate and compare the cost-effectiveness and safety of nebivolol with
sustained-release metoprolol in reducing blood pressure by 1 mm of Hg per day in …

Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …

Objectives The aims of the present study were to determine (1) the β 1-blocking potency and
(2) the β 1 adrenoceptor selectivity of nebivolol in man after repeated dosing (7 days) …

This double‐blind, parallel‐group study compared the effects of Nebivolol, a novel
cardioselective β‐blocker, with those of nifedipine sustained‐release on 24‐hour …